Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 846-855

  Shachter, Neil S ^a   Ebara, Tetsu ^a   Ramakrishnan, Rajasekhar ^a   Steiner, George ^b   Breslow, Jan L ^c   Ginsberg, Henry N ^a   Smith, Jonathan D ^c  

^a Coll Phys Surgs of Columbia Univ ^*  (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

apolipoprotein C; hypertriglyceridemia; lipoproteins, LDL; lipoproteins, VLDL; mice, transgenic

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C1; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HYPERLIPIDEMIA; LIPOPROTEIN SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029862110     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118857     Document Type: Article

References (56)

1. Brown, W.V., R.I. Levy, and D.S. Frederickson. 1969. Studies of the proteins in human plasma very low density lipoproteins J. Biol. Chem. 244:5687-5694.
2. Brown, W.V., R.I. Levy, and D.S. Frederickson. 1970. Further characterization of the apolipoproteins from the human plasma very low density lipoproteins. J. Biol. Chem. 245:6588-6594.
3. LaRosa, J.C., R.I. Levy, P. Herbert, S.E. Lux, and D.S. Frederickson. 1970. A specific apoprotein activator for lipoprotein lipase. Biochem. Biophys. Res. Commun. 41:57-62.
4. Havel, R.J., C.J. Fielding, T. Olivecrona, V.G. Shore, P.E. Fielding, and T. Egelrud. 1973. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry. 12:1828-1833.
5. Brown, W.V., and M.L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun. 46:375-382.
6. Carlson, L.A., and D. Ballantyne. 1976. Changing relative proportions of apolipoprotein C-II and C-III of very low density lipoproteins in hypertriglyceridemia. Atherosclerosis. 23:563-568.
7. Le, N.-A., J.C. Gibson, and H.N. Ginsberg. 1988. Independent regulation of plasma lipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J. Lipid Res. 29:669-677.
8. Wang, C.-S., W.J. McConathy, H.U. Kloer, and P. Alaupovic. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75:384-390.
9. Ginsberg, H.N., N.-A. Le, I.J. Goldberg, J.C. Gibson, A. Rubinstein, P. Wang-Iverson, R. Norum, and W.V. Brown. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78:1287-1295.
10. Dammerman, M., L.A. Sankuijl, J. Halaas, W. Chung, and J.L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90:4562-4566.
11. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J.L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (Wash. DC). 249:790-793.
12. Aalto-Setälä, K., E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein (VLDL) fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90:1889-1900.
13. de Silva, H.V., S.J. Lauer, J. Wang, W.S. Simonet, K.H. Weisgraber, R.W. Mahley, and J.M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269:2324-2335.
14. Maeda, N., H. Li, D. Lee, P. Oliver, S.H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269:23610-23616.
15. Shachter, N.S., T. Hayek, T. Leff, J.D. Smith, D.W. Rosenberg, A. Walsh, R. Ramakrishnan, I.J., Goldberg, H.N. Ginsberg, and J.L. Breslow. 1994. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J. Clin. Invest. 93:1683-1690.
16. Windler, E., Y. Chao, and R.J. Havel. 1980. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apolipoproteins. J. Biol. Chem. 255: 8303-8307.
17. Quarfordt, S.H., G. Michalopoulos, and B. Schirmer. 1982. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J. Biol. Chem. 257:14642-14647.
18. Kowal, R.C., J. Herz, K.H. Weisgraber, R.W. Mahley, M.S. Brown, and J.L. Goldstein. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
19. Weisgraber, K.H., R.W. Mahley, R.C. Kowal, J. Herz, J.L. Goldstein, and M.S. Brown. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:22453-22459.
20. Windler, E.E., P.T. Kovanen, Y.S. Chao, M.S. Brown, R.J. Havel, and J.L. Goldstein. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem. 255:10464-10471.
21. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266:18259-18267.
22. Simonet, W.S., N. Bucay, R.E. Pitas, S.J. Lauer, and J.M. Taylor. 1991. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J. Biol. Chem. 266:8651-8654.
23. van Rec, J.H., M.H. Hofker, W.J. van den Broek, J.M. van Deursen, H. van der Boom, R.R. Frants, B. Wieringa, and L.M. Havekes. 1995. Increased response to cholesterol feeding in apolipoprotein CI-deficient mice. Biochem. J. 305:905-911.
24. Shachter, N.S., Y. Zhu, A. Walsh, J.L. Breslow, and J.D. Smith. 1993. Localization of a liver-specific enhancer in the apolipoprotein E/CI/CII gene locus. J. Lipid Res. 34:1699-1708.
25. Smit, M., E. van der Kooij-Meijs, L.P. Woudt, L.M. Havekes, and R.R. Frants. 1988. Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOCI gene. Biochem. Biophys. Res. Commun. 152:1282-1288.
26. 3. J. Biol. Chem. 264:6488-6494.
27. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setälä, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1-20.
28. Knott, T.J., M.E. Robertson, L.M. Priestly, M. Urdea, S. Wallis, and J. Scott. 1984. Characterisation of mRNAs encoding the precursor for human apolipoprotein CI. Nucleic Acids Res. 12:3909-3915.
29. Smith, J.D., A.S. Plump, T. Hayek, A. Walsh, and J.L. Breslow. 1990. Accumulation of human apolipoprotein E in the plasma of transgenic mice. J. Biol. Chem. 265:14709-14712.
30. Curry, M.D., W.J. McConathy, J.D. Fesmire, and P. Alaupovic. 1981. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electroimmunoassays. Clin. Chem. 27:543-548.
31. Havel, R.J., H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
32. Herbert, P.N., R.S. Shulman, R.I. Levy, and D.S. Frederickson. 1973. Fractionation of the C-apolipoproteins from human plasma very low density lipoproteins. J. Biol. Chem. 248:4941-4946.
33. Pagnan, A., R.J. Havel, J.P. Kane, and L. Kotite. 1977. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J. Lipid Res. 18:613-622.
34. Ginsberg, H.N., N.-A. Le, and J.C. Gibson. 1985. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects: effect of weight loss. J. Clin. Invest. 75:614-623.
35. Bilheimer, D.W., J. Eisenberg, and R.I. Levy. 1972. The metabolism of very low density lipoproteins. I. Preliminary in vivo and in vitro observations. Biochim. Biophys. Acta. 26:212-221.
36. Levine, D.M., and K.J. Williams. 1995. Mouse apolipoprotein B: a useful screening tool for mouse models of atherosclerosis. Clin. Chem. 41:139-140. (Abstr.)
37. Attman, P.O., P. Alaupovic, and A. Gustafson. 1987. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int. 32:368-375.
38. Albers, J.J., J. Lin, and G.P. Roberts. 1979. Effect of human plasma apolipoproteins on the activity of purified lecithin: cholesterol acyltransferase. Artery. 5:61-75.
39. Plump, A.S., and J.L. Breslow. 1995. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu. Rev. Nutr. 15:495-518.
40. Simonet, W.S., N. Bucay, S.J. Lauer, and J.M. Taylor. 1993. A far-down-stream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J. Biol. Chem. 268: 8221-8229.
41. Dang, Q., D. Walker, S. Taylor, C. Allan, P. Chin, J. Fan, and J. Taylor. 1995. Structure of the Hepatic Control Region of the human apolipoprotein E/ C-I gene locus. J. Biol. Chem. 270:22577-22585.
42. Woolett, L.A., D.K. Spady, and J.M. Dietschy. 1992. Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. J. Lipid Res. 33:77-88.
43. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 57:65-73.
44. Attman, P.-O., and P. Alaupovic. 1991. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron. 57:401-410.
45. Windler, E., and R.J. Havel. 1985. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26:556-565.
46. Linton, M.F., R.W. Farese, Jr., G. Chiesa, D.S. Grass, P. Chin, R.E. Hammer, H.H. Hobbs, and S.G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92:3029-3037.
47. Kessling, A.M., M.N. Nanjee, N.E. Miller, and S.E. Humphries. 1988. Variations in the apolipoprotein AI-CIII-AIV gene region and in lecithin:cholesterol acyltransferase concentration are determinants of plasma cholesterol concentrations. Atherosclerosis. 70:13-19.
48. Glomset, J.A., E.T. Janssen, R. Kennedy, and J. Dobbins. 1966. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J. Lipid Res. 7:638-648.
49. Fielding, P.E., and C.J. Fielding. 1980. A cholesteryl ester transfer complex in human plasma. Proc. Natl. Acad. Sci. USA. 77:3327-3330.
50. Nishina, P.M., J.P. Johnson, J.K. Naggert, and R.M. Krauss. 1992. Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc. Natl. Acad. Sci. USA. 89: 708-712.
51. Tybjaerg-Hansen, A., B.G. Nordestgaard, L.U. Gerdes, O. Faergeman, and S.E. Humphries. 1993. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis. 100:157-169.
52. Sijbrands, E.J., R.G. Westendorp, M.J. Hoffer, L.M. Havekes, R.R. Frants, A.E. Meinders, M. Frolich, and A.H. Smelt. 1994. Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler. Thromb. 14:1576-1580.
53. Reynisdottir, S., M. Eriksson, B. Angelin, and P. Arner. 1995. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J. Clin. Invest. 95:2161-2169.
54. Mailly, F., Y. Tugrul, P.W. Reymer, T. Bruin, M. Seed, B.F. Groenemeyer, A. Asplund-Carlson, D. Vallance, A.F. Winder, G.J. Miller et al. 1995. A common variant in the gene for lipoprotein lipase (Asp9->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler. Thromb. 15:468-478.
55. Kwiterovich, P.O., Jr., M. Motevalli, and M. Miller. 1994. The effect of three serum basic proteins on the mass of lipids in normal and hyperapoB fibroblasts. Arterioscler. Thromb. 14:1-7.
56. Klasen, E.C., P.J. Talmud, L. Havekes, E. de Wit, E. van der Kooij-Meijs, M. Smit, G. Hansson, and S.E. Humphries. 1987. A common restriction fragment length polymorphism of the human apolipoprotein E gene and its relationship to type III hyperlipidemia. Hum. Genet. 75:244-247.